Table 2.
Baseline biomarker levels.
| Biomarker | Heberden’s OA | Bouchard’s OA | Pre-Group | Post-Group | p-Value |
|---|---|---|---|---|---|
|
CPII (µg/mL) |
2.0 ± 1.0 1.9 (1.4–2.5) |
1.5 ± 0.6 1.6 (0.9–2.0) |
1.6 ± 0.8 1.8 (0.7–2.1) |
1.9 ± 1.4 2.0 (0.8–3.0) |
0.1372 |
|
C1,2C (ng/mL) |
691 ± 287 621 (499–910) |
605 ± 164 571 (524–711) |
556 ± 144 549 (471–595) |
931 ± 1087 586 (519–822) |
0.4890 |
|
COMP (µg/mL) |
1.8 ± 0.4 1.8 (1.6–2.0) |
2.0 ± 0.3 2.0 (1.8–2.3) |
1.2 ± 0.3 1.1 (1.0–1.5) |
1.7 ± 0.4 1.6 (1.3–2.1) |
0.0605 |
|
sVCAM1 (ng/mL) |
522 ± 288 462 (272–669) |
485 ± 251 497 (289–700) |
585 ± 220 627 (404–699) |
587 ± 136 588 (512–686) |
0.2690 |
|
NGAL (ng/mL) |
100 ± 52.0 97.5 (56.9–126) |
113 ± 32.7 107 (92.9–127) |
120 ± 58.2 108 (79.8–125) |
128 ± 72.5 102 (73.0–161) |
0.5063 |
|
PIIANP (ng/mL) |
1394 ± 383 1285 (1163–1609) |
1389 ± 487 1210 (1059–1791) |
1027 ± 294 893 (830–1216) |
1172 ± 386 1029 (946–1353) |
0.0070 |
Data shown represent the means ± standard deviations, medians with interquartile ranges in brackets, and the p-values of the Kruskal–Wallis test. Pre-group = premenopausal control group, Post-group = postmenopausal control group.